Dr. Natalie Galant is the CEO and co-founder of the Paradox Immunotherapeutics, a pharmaceutical company dedicated to the creation of antibody therapies for the treatment of rare protein misfolding diseases.
Prior to taking on this role, Natalie received her PhD from the University of Toronto’s Department of Medical Biophysics where her PhD thesis helped lead to the development of a monoclonal antibody that was acquired by Novo Nordisk from Prothena Biosciences in a $1.2B acquisition deal (2021) and is currently is Phase 2 FDA clinical trials.
Additionally, she is the recipient of numerous academic fellowships, the winner of multiple pitch competitions, including $250,000 from Canada’s largest non-dilutive start-up pitch competition, the Ted Rogers Centre for Heart Research ECHO competition.
Prior to taking on this role, Natalie received her PhD from the University of Toronto’s Department of Medical Biophysics where her PhD thesis helped lead to the development of a monoclonal antibody that was acquired by Novo Nordisk from Prothena Biosciences in a $1.2B acquisition deal (2021) and is currently is Phase 2 FDA clinical trials.
Additionally, she is the recipient of numerous academic fellowships, the winner of multiple pitch competitions, including $250,000 from Canada’s largest non-dilutive start-up pitch competition, the Ted Rogers Centre for Heart Research ECHO competition.
Speaking In
11:00 AM - 1:00 PM
Wednesday, June 7
